On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa.  CT-P17 is a high-concentration, low-volume and citrate-free adalimumab biosimilar, indicated for the treatment of a number of conditions including rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease.  According to Hikma, CT-P17 provides pain-reducing features and causes less pain upon injection.  The partnership agreement would give Hikma exclusive rights to commercialize YUFLYMA in all of its Middle East/North Africa markets.

[View source.]